John Joseph Johnston Sells 3,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

by · The Cerbat Gem

MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) Director John Joseph Johnston sold 3,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $3.72, for a total transaction of $11,160.00. Following the transaction, the director now directly owns 141,950 shares in the company, valued at approximately $528,054. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

John Joseph Johnston also recently made the following trade(s):

  • On Thursday, September 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $3.82, for a total transaction of $11,460.00.
  • On Monday, August 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $4.28, for a total transaction of $12,840.00.

MaxCyte Price Performance

Shares of NASDAQ:MXCT opened at $3.58 on Friday. The business’s 50 day simple moving average is $3.91 and its 200 day simple moving average is $4.18. MaxCyte, Inc. has a 1 year low of $2.92 and a 1 year high of $5.55.

MaxCyte (NASDAQ:MXCT – Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.05. The company had revenue of $10.43 million for the quarter, compared to analyst estimates of $8.20 million. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. During the same period in the prior year, the firm posted ($0.10) EPS. On average, equities analysts predict that MaxCyte, Inc. will post -0.44 EPS for the current year.

Hedge Funds Weigh In On MaxCyte

Hedge funds have recently bought and sold shares of the company. Swedbank AB acquired a new stake in shares of MaxCyte during the 1st quarter worth approximately $6,704,000. Chevy Chase Trust Holdings LLC lifted its stake in MaxCyte by 2,182.6% during the first quarter. Chevy Chase Trust Holdings LLC now owns 1,296,397 shares of the company’s stock worth $5,432,000 after purchasing an additional 1,239,602 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of MaxCyte in the 2nd quarter valued at $1,959,000. River Global Investors LLP increased its stake in shares of MaxCyte by 24.4% in the 1st quarter. River Global Investors LLP now owns 1,888,642 shares of the company’s stock valued at $7,973,000 after purchasing an additional 369,996 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of MaxCyte by 13.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,010,292 shares of the company’s stock worth $3,961,000 after buying an additional 121,090 shares in the last quarter. 68.81% of the stock is owned by institutional investors.

MaxCyte Company Profile

(Get Free Report)

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Read More